4SC AG (FRA:VSC) EV-to-OCF: (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 4SC AG EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, 4SC AG's Enterprise Value is €-4.11 Mil. 4SC AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil. Therefore, 4SC AG's EV-to-OCF for today is .

The historical rank and industry rank for 4SC AG's EV-to-OCF or its related term are showing as below:

During the past 13 years, the highest EV-to-OCF of 4SC AG was 1.41. The lowest was -19.41. And the median was -2.71.

FRA:VSC's EV-to-OCF is not ranked *
in the Biotechnology industry.
Industry Median: -3.45
* Ranked among companies with meaningful EV-to-OCF only.

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-09), 4SC AG's stock price is €0.10. 4SC AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.367. Therefore, 4SC AG's PE Ratio (TTM) for today is At Loss.


4SC AG  (FRA:VSC) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

4SC AG's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.10/-0.367
=At Loss

4SC AG's share price for today is €0.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 4SC AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.367.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.


4SC AG EV-to-OCF Related Terms


4SC AG EV-to-OCF Historical Data

* Premium members only.

The historical data trend for 4SC AG's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4SC AG EV-to-OCF Chart

4SC AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-OCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.54 0.20 -8.50 -4.69 0.00

4SC AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.50 0.00 -4.69 0.00 0.00

FRA:VSC vs VRTX, REGN, ALNY: EV-to-OCF Comparison

For the Biotechnology subindustry, 4SC AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4SC AG EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4SC AG's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where 4SC AG's EV-to-OCF falls into.



4SC AG EV-to-OCF Calculation

4SC AG's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=-4.111/0
=

4SC AG's current Enterprise Value is €-4.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 4SC AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4SC AG Business Description

Address Fraunhoferstrasse 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.